When is it appropriate to use concomitant immunomodulators with anti-TNF agents for the treatment of Crohn’s disease?

Below you can input patient characteristics and see the BRIDGe RAND panel’s recommendations for the use of monotherapy versus combination therapy for the treatment of Crohn’s disease. Assuming that ALL patients will receive an anti-TNF agent, the output will be the appropriateness of also using an immunomodulator.
Patient type
Patients were categorized into five different scenarios. Please choose the scenario that best fits the patient in question:
Disease variables
Now, please select the disease variables that best describes the patient in question: